T.-Y. Kim

IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)

Ann‐Lii Cheng, S. Qin, Masafumi Ikeda et al. · Annals of Oncology · 2019 · 196 citations

Medicine, Oncology, Pharmacology +11

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

K. Park, Johan Vansteenkiste, Ki Hyeong Lee et al. · Annals of Oncology · 2020 · 114 citations · Full text

Medicine, Cancer Biology, Oncology +11

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

Ignacio Melero, Thomas Yau, Yoon‐Koo Kang et al. · Annals of Oncology · 2024 · 87 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma

Salah‐Eddin Al‐Batran, Eric Van Cutsem, Sang Cheul Oh et al. · Annals of Oncology · 2016 · 76 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040

Anthony B. El-Khoueiry, Jörg Trojan, Tim Meyer et al. · Annals of Oncology · 2023 · 63 citations · Full text

Medicine, Oncology, Pharmacotherapy +17